Statin and Cancer Mortality and Survival: An Umbrella Systematic Review and Meta-Analysis.
cancer mortality
cancer survival
meta-analysis
statin
umbrella review
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
23 Jan 2020
23 Jan 2020
Historique:
received:
09
12
2019
revised:
07
01
2020
accepted:
20
01
2020
entrez:
26
1
2020
pubmed:
26
1
2020
medline:
26
1
2020
Statut:
epublish
Résumé
The aim of this study is to provide an overview and understand the strength of evidence and the extent of potential biases and the validity of claimed associations between the use of statins and cancer mortality or survival. We performed a comprehensive umbrella review of meta-analyses and systematically appraised the relevant meta-analyses of observational studies on the associations between statin use and cancer mortality or survival in various kinds of cancer. We searched the PubMed database and screened the reference list of relevant articles. We obtained the summary effect, 95% confidence interval, heterogeneity, and also examined small study effects and 95% prediction intervals for effect sizes, and the level of evidence was determined from the criteria. Regarding cancer mortality, statin use showed convincing evidence for an association with a reduced cancer-specific mortality rate for colorectal cancer. Four associations with reduced all-cause mortality (for breast cancer, colorectal cancer, endocrine-related gynecological cancer, and ovarian cancer) had a suggestive evidence. Moreover, analyses in nine cancers showed a weak level of evidence, while the remaining 15 did not indicate significant changes in either direction. Although there was a preventive effect of statin on cancer mortality in some cancer types, the evidence supporting the use of statins to reduce cancer mortality or survival was low.
Identifiants
pubmed: 31979352
pii: jcm9020326
doi: 10.3390/jcm9020326
pmc: PMC7074262
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Int J Cancer. 2008 Aug 15;123(4):951-7
pubmed: 18521906
Milbank Q. 2016 Sep;94(3):485-514
pubmed: 27620683
Oncotarget. 2017 Jun 20;8(25):41508-41517
pubmed: 28489569
Ann Oncol. 2018 Mar 1;29(3):749-757
pubmed: 29300814
Cancer Epidemiol. 2016 Dec;45:71-81
pubmed: 27750068
Cancer Treat Rev. 2015 Jun;41(6):554-67
pubmed: 25890842
Lancet Oncol. 2014 Jan;15(1):23-34
pubmed: 24314615
Gut. 2010 Nov;59(11):1572-85
pubmed: 20660702
JAMA. 1996 Jan 3;275(1):55-60
pubmed: 8531288
J Cancer Res Ther. 2012 Apr-Jun;8(2):176-83
pubmed: 22842358
BMJ. 2007 Jan 13;334(7584):94-6
pubmed: 17218716
Onco Targets Ther. 2016 Mar 21;9:1689-96
pubmed: 27051303
J Clin Med. 2019 Jun 08;8(6):
pubmed: 31181789
Curr Med Chem. 2018;25(22):2595-2607
pubmed: 28403788
PLoS One. 2013;8(3):e59202
pubmed: 23544056
Medicine (Baltimore). 2015 Jun;94(25):e908
pubmed: 26107680
PLoS One. 2015 Jun 01;10(6):e0126944
pubmed: 26030771
Cancer Treat Rev. 2017 Jan;52:105-116
pubmed: 27992843
BMJ. 2013 Jul 19;347:f4501
pubmed: 23873947
Nat Rev Cancer. 2005 Dec;5(12):930-42
pubmed: 16341084
N Engl J Med. 1996 Oct 3;335(14):1001-9
pubmed: 8801446
N Engl J Med. 1987 Feb 19;316(8):450-5
pubmed: 3807986
Prostate Cancer Prostatic Dis. 2016 Jun;19(2):151-62
pubmed: 26782711
Cancer Chemother Pharmacol. 2011 Apr;67(4):729-39
pubmed: 21327931
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Int J Oncol. 2003 Oct;23(4):1055-69
pubmed: 12963986
JAMA. 2006 Jan 4;295(1):74-80
pubmed: 16391219
Circulation. 1992 Sep;86(3):1026-9
pubmed: 1516172
BMJ. 2017 Feb 28;356:j477
pubmed: 28246088
Lancet. 1994 Nov 19;344(8934):1383-9
pubmed: 7968073
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
J R Stat Soc Ser A Stat Soc. 2009 Jan;172(1):137-159
pubmed: 19381330
J Nutr Biochem. 2008 Jul;19(7):448-58
pubmed: 17869085
Int J Cancer. 2017 Mar 1;140(5):1068-1081
pubmed: 27859151
J Clin Epidemiol. 2009 Oct;62(10):e1-34
pubmed: 19631507
Ann Oncol. 2017 Jun 1;28(6):1169-1182
pubmed: 28327894
Clin Cancer Res. 2003 Jan;9(1):10-9
pubmed: 12538446
Ann Oncol. 2013 Jun;24(6):1427-34
pubmed: 23508824
Expert Opin Drug Saf. 2010 Jul;9(4):603-21
pubmed: 20377474
Br J Clin Pharmacol. 2018 Jun;84(6):1109-1120
pubmed: 29453799
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Int J Cancer. 2016 Sep 15;139(6):1281-8
pubmed: 27176735
Gastroenterology. 2007 Oct;133(4):1272-81
pubmed: 17919499
Eur J Cancer. 2016 Dec;69:61-69
pubmed: 27816833
J Pharm Pharm Sci. 2016;19(1):72-81
pubmed: 27096694
J Epidemiol. 2017 Mar;27(3S):S84-S91
pubmed: 28196737
BMJ. 2011 Jul 22;343:d4002
pubmed: 21784880
Medicine (Baltimore). 2015 Sep;94(36):e1523
pubmed: 26356727
Breast Cancer Res Treat. 2017 Jul;164(1):1-11
pubmed: 28432513
CMAJ. 2009 Oct 13;181(8):488-93
pubmed: 19654195